



PRODUCT: **Nurtec® ODT**

COMPANY: Biohaven Pharmaceuticals

THERAPEUTIC AREA & INDICATION:
Acute treatment of migraine

ABOUT THE PRODUCT

Nurtec® ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration for the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults. Nurtec ODT allows a patient to manage their migraine with a single medication with a simple dose of 75 mg, taken as needed, up to once daily to treat or every other day to help prevent migraine attacks.